5/2/2025

COPENHAGEN, Denmark, May 02, 2025--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one prior systemic therapy.

Source: Yahoo

5/1/2025

We recently published a list of 13 Most Profitable Growth Stocks to Buy Now. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other most profitable growth stocks to buy now. The growth factor in investing refers to companies that grow their revenue and earnings at rates […]

Source: Yahoo

4/28/2025

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 21 to April 25, 2025: Trading PlatformNo. of sharesAve

Source: Yahoo

4/27/2025

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV stock with a Strong Buy rating.

Source: SeekingAlpha

4/24/2025

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain bullish on JNJ stock.

Source: SeekingAlpha

4/20/2025

Source: SeekingAlpha

4/16/2025

GMAB vs. RGEN: Which Stock Is the Better Value Option?

Source: Yahoo

4/16/2025

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Source: Yahoo

4/15/2025

Genmab (CPSE:GMAB) recently reported impressive first-quarter 2025 trade sales for DARZALEX, totaling USD 3,237 million, with strong performance both in the U.S. and internationally. Over the past week, the stock price increased by 1.93%, a movement aligned with broader market trends which saw a 6.8% rise. While Genmab's robust sales data for DARZALEX could have added weight to its market performance, the broader economic environment was influenced by tech and financial sectors leading U.S...

Source: Yahoo

4/15/2025

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor

Source: Yahoo

4/15/2025

Source: SeekingAlpha

4/10/2025

Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expe

Source: Yahoo

4/2/2025

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at whereGenmab A/S (NASDAQ:GMAB) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining […]

Source: Yahoo

4/1/2025

Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genm

Source: Yahoo

4/1/2025

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in […]

Source: Yahoo

3/31/2025

COPENHAGEN, Denmark, March 31, 2025--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic ce

Source: Yahoo

3/31/2025

The scientists trying to find a cure for cancer know they have to be patient. Likewise, most shareholders who back companies at the forefront of these medical endeavours know they are playing the long game.

Source: Yahoo

3/28/2025

The approval is based on open-label Phase III innovaTV 301 clinical trial data.

Source: Yahoo

3/27/2025

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan. The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced

Source: Yahoo

3/27/2025

COPENHAGEN, Denmark, March 27, 2025--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.

Source: Yahoo